此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

One-Day cTBS Over the Precuneus (OcTOPUS)

2026年9月8日 更新者：Hakjoo Kim、Mclean Hospital

One-Day cTBS Over the Precuneus (OcTOPUS)

The goal of this clinical trial is to learn whether two forms of one-day accelerated transcranial magnetic stimulation (TMS) can reduce depressive symptoms in adults with treatment-resistant depression. Treatment-resistant depression is depression that has not improved enough after at least two adequate antidepressant medication treatments. TMS is a non-invasive treatment that uses magnetic pulses to stimulate specific areas of the brain.

The main questions this study aims to answer are:

  • Does continuous theta-burst stimulation (cTBS) targeting the precuneus reduce depressive symptoms 4 weeks after treatment compared with sham stimulation?
  • Does intermittent theta-burst stimulation (iTBS) targeting the left dorsolateral prefrontal cortex reduce depressive symptoms 4 weeks after treatment compared with sham stimulation?

Researchers will compare precuneus cTBS, left dorsolateral prefrontal cortex iTBS, and sham stimulation to determine whether either active treatment reduces depressive symptoms more than sham stimulation. Participants will be randomly assigned to one of the three groups and will not be told which treatment they initially receive.

Participants will:

  • Complete screening procedures and baseline assessments of depression, rumination, and cognitive function
  • Receive 20 sessions of active or sham TMS during one in-person study day
  • Complete follow-up assessments 1, 2, 3, and 4 weeks after the intervention
  • Report any side effects or medical problems experienced during the study

Participants initially assigned to sham stimulation may choose to receive active TMS after completing the 4-week follow-up period. Those who choose this option will receive either precuneus cTBS or left dorsolateral prefrontal cortex iTBS and will complete additional follow-up assessments.

研究概览

地位

招聘中

条件

干预/治疗

详细说明

Treatment-resistant depression may involve dysfunction across distributed brain networks rather than a disturbance confined to a single brain region. The precuneus is a posterior hub of the default mode network and is involved in internally directed and self-referential processing. Altered interactions among the default mode, affective, and cognitive control networks have been implicated in depressive symptoms and rumination. In this study, precuneus continuous theta-burst stimulation (cTBS) is conceptualized as a hypothesis-driven network intervention that may modulate precuneus-centered network interactions implicated in depression.

A double-cone coil will be used to increase electric-field penetration toward the medial posteromedial cortex beneath the Pz scalp location of the international 10-20 electroencephalography system. Intermittent theta-burst stimulation (iTBS) of the left dorsolateral prefrontal cortex is included as an additional active treatment arm because this region is an established stimulation target for depression treatment. The three-arm design allows the novel precuneus target and the established left dorsolateral prefrontal cortex target to be evaluated within the same accelerated treatment framework and compared with sham stimulation.

Participants will be assigned to the three initial study groups using the minimal sufficient balance (MSB) randomization method, with sex and baseline depression severity, as measured by the Montgomery-Åsberg Depression Rating Scale, used as balancing factors. The target allocation ratio for the randomized, sham-controlled phase will be 1:1:1. Group allocation will be concealed from participants. Each active or sham intervention will consist of 20 stimulation sessions administered during a single day, with session onsets separated by approximately 30 minutes.

The primary efficacy analyses will use a longitudinal mixed-model framework to estimate treatment effects and evaluate the two prespecified active-versus-sham comparisons. The familywise type I error rate will be controlled across these two comparisons. The direct comparison between precuneus cTBS and left dorsolateral prefrontal cortex iTBS will be considered exploratory.

After completing the 4-week follow-up period, participants initially assigned to sham stimulation may elect to enter an open-label active TMS extension. Extension participants will be assigned to precuneus cTBS or left dorsolateral prefrontal cortex iTBS using the MSB method, with a target allocation ratio of 1:1. Sex and depression severity at the end of the sham-controlled phase, as measured by the Week 4 Montgomery-Åsberg Depression Rating Scale score, will be used as balancing factors. Because only a subset of participants assigned to sham stimulation is expected to enter the extension, extension analyses will be considered exploratory and hypothesis-generating.

研究类型

介入性

注册 (估计的)

69

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名：Hakjoo Kim Kim, Ph.D.
  • 电话号码：979-777-0679
  • 邮箱：khj213@gmail.com

学习地点

  • 美国
    • Massachusetts
      • Belmont、Massachusetts、美国、02478
        • 招聘中
        • Mclean Hospital
        • 接触：
        • 首席研究员：
          • Hakjoo Kim, PhD

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Age 18 years or older.
  • Able to speak, read, and understand English sufficiently to complete the study assessments and provide informed consent independently.
  • Diagnosis of major depressive disorder according to DSM-5-TR criteria, confirmed by a qualified physician.
  • Treatment-resistant depression, defined as an inadequate response to at least two adequate trials of antidepressant pharmacotherapy.
  • Patient Health Questionnaire-9 (PHQ-9) total score of 10 or higher.

Exclusion Criteria:

  • Any condition identified through TMS safety screening that, in the judgment of a study physician, presents an unacceptable safety risk for TMS. Such conditions may include:
  • A history of a serious adverse reaction during TMS treatment.
  • A history of seizure.
  • A history of stroke.
  • A history of serious head injury or neurosurgery.
  • Metal in the head outside the mouth, such as shrapnel, surgical clips, or metal fragments.
  • An implanted device, such as a cardiac pacemaker, cochlear implant, medical pump, or intracardiac line.
  • Frequent or severe headaches.
  • Another brain-related condition or an illness that caused brain injury.
  • A family history of epilepsy.
  • Permanent tattoos on the head or neck.
  • Current recreational drug use.
  • Current pregnancy or possible pregnancy.
  • Use of a medication or combination of medications, a recent medication change, or medication withdrawal that, in the judgment of a study physician, presents an unacceptable safety risk, including a clinically significant increase in seizure risk.
  • Current or lifetime diagnosis of bipolar I disorder, bipolar II disorder, a schizophrenia spectrum disorder, or another primary psychotic disorder.
  • Active suicidal ideation with intent or plan requiring immediate clinical intervention, or another acute safety concern that cannot be safely managed within the study.

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：随机化
  • 介入模型：并行分配
  • 屏蔽：单身的

武器和干预

参与者组/臂
干预/治疗
实验性的：Precuneus cTBS
Participants receive 20 sessions of active continuous theta-burst stimulation (cTBS) targeting the Pz location of the international 10-20 EEG system during a single day. Stimulation is delivered using a double-cone coil at 80% of the participant's resting motor threshold. Each session consists of 600 pulses delivered over approximately 40 seconds, for a total of 12,000 pulses. Session onsets are separated by approximately 30 minutes. If stimulation at 80% of resting motor threshold is not tolerated, the intensity may be reduced to the highest tolerable level.
设备：Precuneus-targeted continuous theta-burst stimulation
Active continuous theta-burst stimulation is delivered to the Pz location of the international 10-20 EEG system to target the precuneus. Stimulation is administered with a double-cone coil at 80% of the participant's resting motor threshold. Each session consists of 600 pulses delivered over approximately 40 seconds. Participants receive 20 sessions during a single day, for a total of 12,000 pulses, with session onsets separated by approximately 30 minutes. If 80% of resting motor threshold is not tolerated, the intensity may be reduced to the highest tolerable level.
其他名称：
  • 持续的θ爆发刺激
  • Precuneus cTBS
实验性的：Left dlPFC iTBS
Participants receive 20 sessions of active intermittent theta-burst stimulation (iTBS) targeting the left dorsolateral prefrontal cortex during a single day. The target is identified using the Beam F3 method, and stimulation is delivered using a figure-of-eight coil at 80% of the participant's resting motor threshold. Each session consists of 600 pulses delivered over approximately 3 minutes, for a total of 12,000 pulses. Session onsets are separated by approximately 30 minutes. If stimulation at 80% of resting motor threshold is not tolerated, the intensity may be reduced to the highest tolerable level.
设备：Left dorsolateral prefrontal cortex intermittent theta-burst stimulation
Active intermittent theta-burst stimulation is delivered to the left dorsolateral prefrontal cortex. The stimulation target is identified using the Beam F3 method. Stimulation is administered with a figure-of-eight coil at 80% of the participant's resting motor threshold. Each session consists of 600 pulses delivered over approximately 3 minutes. Participants receive 20 sessions during a single day, for a total of 12,000 pulses, with session onsets separated by approximately 30 minutes. If 80% of resting motor threshold is not tolerated, the intensity may be reduced to the highest tolerable level.
其他名称：
  • 间歇性θ波刺激
  • Left dlPFC iTBS
假比较器：Sham TMS
Participants receive 20 sessions of sham TMS at the left dorsolateral prefrontal cortex location identified using the Beam F3 method during a single day. A figure-of-eight coil is inverted so that the active surface faces away from the scalp. The device is operated at 80% of the participant's resting motor threshold, and sham stimulation follows the same stimulation pattern and approximate 3-minute duration as active iTBS. Session onsets are separated by approximately 30 minutes. After completing the Week 4 assessment, participants may enter an optional open-label extension and are randomized to receive active precuneus cTBS or left dlPFC iTBS.
设备：Sham transcranial magnetic stimulation
Sham transcranial magnetic stimulation is administered at the left dorsolateral prefrontal cortex location identified using the Beam F3 method. A figure-of-eight coil is inverted so that the active surface faces away from the scalp. The stimulator is operated at 80% of the participant's resting motor threshold using the same intermittent theta-burst timing and approximate session duration as the active left dorsolateral prefrontal cortex intervention. Participants receive 20 sham sessions during a single day, with session onsets separated by approximately 30 minutes.
其他名称：
  • 假 TMS
  • Sham intermittent theta-burst stimulation

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 4
大体时间：Baseline and 1, 2, 3, and 4 weeks after the intervention
The MADRS is a clinician-administered 10-item scale used to assess the severity of depressive symptoms. Each item is scored from 0 to 6, yielding a total score ranging from 0 to 60. Higher scores indicate greater depressive symptom severity. MADRS total scores will be assessed at baseline and at Weeks 1, 2, 3, and 4 after the intervention. Post-intervention scores will be compared between treatment groups with adjustment for baseline MADRS total score. The primary treatment comparison will be conducted at Week 4.
Baseline and 1, 2, 3, and 4 weeks after the intervention

次要结果测量

结果测量
措施说明
大体时间
17-Item Hamilton Depression Rating Scale (HAM-D-17) Total Score Through Week 4
大体时间：Baseline and 1, 2, 3, and 4 weeks after the intervention
The HAM-D-17 is a clinician-administered 17-item scale used to assess the severity of depressive symptoms. The total score ranges from 0 to 52, with higher scores indicating greater depressive symptom severity. HAM-D-17 total scores will be assessed at baseline and at Weeks 1, 2, 3, and 4 after the intervention. Post-intervention scores will be compared between treatment groups with adjustment for baseline HAM-D-17 total score.
Baseline and 1, 2, 3, and 4 weeks after the intervention
Patient Health Questionnaire-9 (PHQ-9) Total Score Through Week 4
大体时间：Baseline and 1, 2, 3, and 4 weeks after the intervention
The PHQ-9 is a 9-item self-report measure used to assess depressive symptom severity. Each item is scored from 0 to 3, yielding a total score ranging from 0 to 27. Higher scores indicate greater depressive symptom severity. PHQ-9 total scores will be assessed at baseline and at Weeks 1, 2, 3, and 4 after the intervention. Post-intervention scores will be compared between treatment groups with adjustment for baseline PHQ-9 total score.
Baseline and 1, 2, 3, and 4 weeks after the intervention
Ruminative Responses Scale (RRS) Total Score Through Week 4
大体时间：Baseline and 1, 2, 3, and 4 weeks after the intervention
The RRS is a 22-item self-report measure used to assess the tendency to engage in ruminative responses. Each item is scored from 1 to 4, yielding a total score ranging from 22 to 88. Higher scores indicate greater levels of rumination. RRS total scores will be assessed at baseline and at Weeks 1, 2, 3, and 4 after the intervention. Post-intervention scores will be compared between treatment groups with adjustment for baseline RRS total score.
Baseline and 1, 2, 3, and 4 weeks after the intervention
Montreal Cognitive Assessment (MoCA) Total Score at Week 4
大体时间：Baseline and 4 weeks after the intervention
The MoCA is a clinician-administered cognitive screening measure that assesses multiple cognitive domains. The total score ranges from 0 to 30, with higher scores indicating better cognitive performance. MoCA total scores will be assessed at baseline and at Week 4 after the intervention. The Week 4 score will be compared between treatment groups with adjustment for baseline MoCA total score.
Baseline and 4 weeks after the intervention
MGH/McLean Objective Neurocognitive Assessment (MONA) Total Score at Week 4
大体时间：Baseline and 4 weeks after the intervention
The MONA is an objective neurocognitive assessment that evaluates multiple cognitive domains. The total score ranges from 0 to 30, with higher scores indicating better cognitive performance. MONA total scores will be assessed at baseline and at Week 4 after the intervention. The Week 4 score will be compared between treatment groups with adjustment for baseline MONA total score.
Baseline and 4 weeks after the intervention

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Mclean Hospital

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年9月8日

初级完成 (估计的)

2027年6月30日

研究完成 (估计的)

2027年6月30日

研究注册日期

首次提交

2026年8月6日

首先提交符合 QC 标准的

2026年8月6日

首次发布 (实际的)

2026年8月11日

研究记录更新

最后更新发布 (实际的)

2026年9月11日

上次提交的符合 QC 标准的更新

2026年9月8日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • 2026P001989

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

不

IPD 计划说明

At this time, there is no plan to share individual participant data because external sharing of participant-level data is not included in the current informed consent and institutional data management plan. Aggregate study results will be disseminated through scientific presentations and publications. Any future sharing of de-identified data would require additional institutional and IRB review and approval.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅